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Anna Finn
Lake Forest College

The Relationship between Self-efficacy and
Health Promoting Behaviors, Illness Severity,
Mental Health, and Perceived Quality of Life
in Multiple Sclerosis Patients

Multiple sclerosis is an incurable, debilitating, nervous system disease,
which causes are largely unknown, and which affects hundreds of thousands of people across the United States. Early research suggests the
impact that psychological factors can have on a patient's physical and
mental health status. Self-efficacy, the belief in one's ability to cope with
a situation, has been found to offer beneficial and protective effects in
patients suffering from conditions such as rheumatoid arthritis, sickle cell
disease, and fibromylagia. This comprehensive literature review sought to
look at psychological research that has considered the relationship between self-efficacy and health promoting behaviors, symptom and overall
illness severity, mental health status, and perceived quality of life in
people suffering from multiple sclerosis. The literature strongly supports
a relationship between self-efficacy and health promoting behaviors. The
literature was ambiguous as to a relationship between self-efficacy and
illness severity—with some studies finding a significant relationship and
others not. The literature reviewed also suggests a potential relationship
between self-efficacy and other cognitive components such as mental
health status, mood control, and self-esteem. The literature supports a
relationship between self-efficacy and perceived quality of life.

Multiple Sclerosis is an incurable,
chronic, debilitating neurological disease that
affects the central nervous system. It is caused
by a destruction and subsequent reduction of
myelin, which acts as a conductor of electrical
impulses, facilitating the transfer of information

between nerves, and also as an insulator, protecting the nerves themselves (About MS). This
demyelination slows the transfer of information
from nerve to nerve and leaves the nerve vulnerable to inflammation and damage, as well as
disrupts the smooth transfer of impulses, leading
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to problems with "vision, strength, sensation,
and coordination" (Shnek et al., 1997, p.187).
Many of the symptoms of multiple sclerosis are
in fact caused by this disruption of the flow of
nerve impulses (Schapiro, 1991, as cited in
Stuifbergen, Seraphine, & Roberts, 2000). These
symptoms include cognitive disturbances, such
as memory, attention, and problem-solving
difficulties, walking difficulties (About MS),
weakness, numbness, fatigue, visual disturbances, dizziness, problems maintaining one's
balance, loss of coordination, bladder and bowel
problems, changes in sexual functioning, pain,
and spasticity.
About 400,000 individuals are currently
diagnosed with MS in the United States, and
there are about 10,000 newly diagnosed cases
each year (Fraser, Hadjimichael, & Vollmer,
2001). Worldwide, it is estimated that 2.5
million individuals have the disease (About MS).
MS is twice more prevalent in women than in
men, and is most common in whites, especially
people with a Northern European background
(About MS). The general age of onset is between
the ages of 20 and 40 (Barnwell & Kavanagh,
1997).
There are two categories of MS: relapsing-remitting MS and progressive MS. The
relapsing-remitting type, the most common form,
is characterized by almost complete recovery
between exacerbations. However, exacerbations
often get progressively worse and can involve
intense neurological dysfunction (Barnwell &
Kavanagh, 1997). Progressive forms of MS,
which are much less common, include primary
progressive MS, progressive-relapsing MS, and
secondary progressive MS. These forms of MS
involve a much more apparent steady reduction
in one's functional ability (Barnwell &
Kavanagh, 1997).
A still not well understood disease, the
causes of MS remain largely unknown. Scientists point to several possible factors, including a
genetic predisposition and environmental triggers such as certain viruses, traumas, and heavy
metals that likely contribute to the development
of MS, though the strength of each contribution

is not known (About MS). The average person
has a 1 in 750 chance of developing MS, while
someone who has a parent with the disease has a
1 in 40 chance (About MS). Furthermore, twin
studies have found that identical twins have a 1
in 3 chance of developing MS if their co-twin
has the disease. While this clearly points to a
genetic component, it also suggests that environmental factors make a difference. Otherwise, the
chance would be much greater than 1 in 3 for
two individuals with the same genetic make up
(About MS). More than likely, there is an interaction effect, whereby one's genetic background
makes an individual especially vulnerable to
developing the disease, but whether or not the
person actually develops the disease is dependent
largely on environmental factors.
A generally erratic, but progressively
worsening illness, consisting either of alternating
periods of stability and exacerbations or steady
decline, multiple sclerosis takes a great toll on
patients' mental health (Wingerson & Wineman,
2000). Because of the day-to-day uncertainty the
illness brings, and the fear of eventual physical
incapacitation, many MS patients are also diagnosed with psychological illnesses, including
most commonly depression (Shnek et al., 1997).
MS patients also have increased rates of emotional distress and are at increased risk for
suicide (Wingerson & Wineman, 2000). With no
cure likely to be found in the near future, medical treatments are still in their very beginning
stages and focus mainly around reducing the
severity of the symptoms and slowing the progression of the disease. With treatments for MS
only available since 1993, researchers have
begun to explore psychological aspects of MS to
determine whether attitudinal factors may affect
the course of the disease, the severity of symptoms, and the mental health of MS patients
(Fraser et al., 2001).
Bandura's social cognitive theory stresses
the importance of self-efficacy, an individual's
confidence that he or she can perform a certain
behavior or cope with a given situation, as a
predictor of future performance. Bandura found
that self-efficacy was a significant predictor of
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not only successful performance, but also of
amount of effort exerted and persistency in
performance despite the presence of obstacles
(Wassem, 1992). Thus, the psychological impact
of self-efficacy is profound; high self-efficacy is
often associated with positive outcome expectations and increased effort and persistence, and
low self-efficacy, with poor outcome expectations and reduced effort (Wassem, 1992). This
theory, which has been repeatedly supported by
scientific findings, suggests that the strength of
self-efficacy as a predictor is not limited to
immediate effects, but that self-efficacy can also
predict long-term outcome variables (Barnwell &
Kavanagh, 1997). Thus, recent research on selfefficacy has largely centered on exploring the
strength of self-efficacy as a predictor of longterm heath promoting behaviors and other
important outcome. variables (Barnwell &
Kavanagh, 1997).
Self-efficacy, the belief that one has the
ability to cope with a situation, has been found to
have significant positive effects on coping,
quality of life, and overall mental health (Riazi,
Thompson, & Hobart, 2004). Research on other
illnesses, specifically rheumatoid arthritis
(Brekke, Hjortdahl, & Kvien, 2001, as cited in
Riazi et al., 2004), sickle cell disease (Edwards,
Telfair, Cecil, & Lenoci, 2001, as cited in Riazi
et al., 2004), and fibromylagia (Buckelew et al.,
1996, as cited in Riazi et al., 2004), has found
that improving self-efficacy has had positive
effects on self-reported health status. Studies
have also found a significant relationship between self-efficacy and other behavioral factors,
such as assisting an individual's adjustment to
the symptoms of their illness, improving adherence to one's medical regimen, quitting smoking
(Borrelli et al., 2002, as cited in Riazi et al.,
2004), reducing one's weight (McCann,
Bovbjerg, Brief, & Turner, 1995, as cited in
Riazi et al., 2004), and increasing one's adherence to exercise programs (Pender, Bar-Or, Wilk,
& Mitchell, 2002, as cited in Riazi et al., 2004)
in individuals with diabetes, alcoholism, depression, cardiac disorders (Wassem, 1992), weight
disorders (Fraser et al., 2001) and a host of other

disorders (Barnwell & Kavanagh, 1997). Therefore, the goal of this paper is to review research
that looks at the relationship between selfefficacy and health promoting behaviors, such as
adherence to medical regimen and physical
activity; symptom and overall illness severity;
mental health status; and perceived quality of life
in patients with multiple sclerosis.

Review of the Literature
The literature reviewed was found using
Medline and Psyclnfo. This literature review is
organized methodologically. The methodological approaches of the 11 journal articles reviewed include two types of designs. One
approach is correlational, and there are several
types of correlational studies reviewed, including
four cross-sectional studies, four longitudinal
studies, and two retrospective studies. A second
method is quasi-experimental, and one of the
studies reviewed had a quasi-experimental
design.
Correlational Studies
Ten correlational studies were reviewed.
While different measures of self-efficacy were
used in many of these studies, all data was
obtained through the use of questionnaires.
Cross-sectional Studies
Four cross-sectional correlational studies
assessed both self-efficacy and a number of
outcome variables of interest, which varied
among the studies. All of the variables were
assessed through the use of questionnaires that
were completed at a single point in time.
Vercoulen et al. (1998) looked at the relationship
between self-efficacy and fatigue, as well as
other symptoms often comorbid with fatigue
syndrome, in 50 Multiple Sclerosis patients. A
diagnosis of MS was confirmed through a full
physical and neurological examination conducted prior to the onset of the study. Information about self-efficacy was obtained through a
single 5-point scale question, as well as through
selected items from the Pain Cognition List
believed to measure self-efficacy. Fatigue was
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measured using the subjective fatigue subscale of efficacy and severity of illness. A significant
the Checklist of Individual Strength. Other
negative relationship was also found between
outcome measures included depression, which
self-efficacy and barriers. A significant positive
was assessed using the Beck Depression Invenassociation was found between self-efficacy and
tory, functional impairment, which was deterresources, acceptance of illness, health-promotmined by the Sickness Impact Profile (SIP),
ing behaviors, and quality of life. All the above
focus on bodily symptoms, which was measured mentioned relationships were assessed using a
through the somatization subscale of the Sympsignificance level of .01.
tom Checklist, and level of physical activity,
Wassem (1992) looked at the strength of
which was assessed through the subscale of
self-efficacy as a predictor of adjustment to
mobility on the SIP and through the Physical
disease in a convenience sample of 62 MS
Activities Rating Scale. Vercoulen et al. (1998)
subjects. A diagnosis of multiple sclerosis was
found, through structural equation modeling, a
determined based on demographic questionsignificant negative relationship between selfnaires, completed at clinic appointments and
efficacy and fatigue. A significant positive
support group meetings of the National MS
association was also found between self-efficacy Society, which included questions about an MS
and level of physical activity. No significant
diagnosis. Self-efficacy was measured using the
relationship was found between self-efficacy and Self-Efficacy for Adjustment Behaviors Scale,
any of the other outcome variables.
which focused on three subscales of adjustment
Stuifbergen et al. (2000) studied the
including psychosocial adjustment, self care
relationship between self-efficacy and health
adjustment, and disease management adjustment.
promoting behaviors, central to one's quality of
Outcome variables included attitudes and behavlife, through questionnaires distributed to 786
iors associated with one's adjustment to his or
subjects with MS. A diagnosis of MS was
her disability, which was assessed using the
assumed, on the basis that the sample was drawn integration subscale of the Bell Disability Scale
from individuals, on the mailing list of the
of Adjustment, and level of disability, which was
National MS Society chapters, who indicated a
measured using the Modified Disability Status
diagnosis of multiple sclerosis. Self-efficacy
Scale. Wassem (1992) found self-efficacy to be
was assessed through the Self-Rated Abilities for a significant predictor of adjustment, accounting
Health Practices scale. Outcome variables
for 24% of the variance in adjustment. Most of
examined in the study were chosen during a
this variance was accounted for by the psychosopreliminary phase of the study, when researchers cial subscale of the Self-Efficacy for Adjustment
tried to identify key variables and antecedents
Behaviors Scale. Demographic variables, selfhighly related to health promoting behaviors and efficacy, and outcome expectations, combined,
perceived quality of life in MS patients. Severity accounted for over half of the variance in adjustof illness was assessed using the Incapacity
ment. Self-efficacy was not found to be a sigStatus Scale, barriers were assessed using the
nificant predictor of severity of illness.
Barriers to Health Promoting Activities for
Shnek et al. (1997) considered the
Disabled Persons Scale, resources were meastrength of self-efficacy as a predictor of depressured through the Personal Resource Questionsion in 80 MS patients. A diagnosis of multiple
naire, acceptance was assessed using the Accep- sclerosis was confirmed based on the diagnostic
tance of Illness Scale, health-promoting behavcriteria established by Pose et al. (1983), through
iors were measured through the Health Promota Medical Information Questionnaire, and also
ing Lifestyle Profile-II, and quality of life was
through medical records. Questionnaires were
measured by the Quality of Life Index.
used to gather data on predictive and outcome
Stuifbergen et al. (2000) found a statistically
variables. Self-efficacy was measured using the
significant negative relationship between selfBeliefs Scale, a modified version of the Arthritis
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Beliefs Scale. Depression was assessed through
the Center for Epidemiologic Studies Depression
Scale. Other variables included level of disability, which was assessed using the Ambulation
and Body Care and Movement Items Scale of the
Sickness Impact Profile; learned helplessness,
which was measured using the Attitudes Index;
cognitive distortions, which was assessed
through the Cognitive Beliefs Questionnaire; and
other demographic and medical information,
including status of employment, number of
medications, and psychiatric disability which
were established using the Medical Information
Questionnaire. Shnek et al. (1997) found selfefficacy to be a significant predictor of depression. Moreover, significant negative relationships were identified between self-efficacy and
cognitive distortions, and between self-efficacy
and helplessness. There was no significant
relationship between self-efficacy and employment, number of medications, psychiatric history,
or disability.
All of the cross-sectional correlational
studies reviewed found a significant relationship
between self-efficacy and at least one of the
outcome variables of interest. Significant positive correlations were found between selfefficacy and a number of outcome variables (e.g.
physical activity, personal resources, acceptance
of illness, health promoting behaviors, quality of
life, and adjustment). Significant negative
correlations were found between self-efficacy
and a number of outcome variables (e.g. fatigue,
barriers to health promoting activities, cognitive
distortions, and helplessness). Ambiguous
findings were reported as to a relationship
between self-efficacy and severity of illness, and
self-efficacy and depression.
Longitudinal Studies
Four of the studies were longitudinal
correlational studies, and assessed both selfefficacy and the outcome variables of interest,
which vary among studies, through the use of
questionnaires completed at two or more points
in time. The follow-up time between the
completion of pre- and post-measures ranged

from six weeks to six months.
Barnwell & Kavanagh (1997) were
interested in the possible relationship between
self-efficacy and psychological adjustment in
multiple sclerosis patients. They looked at two
aspects of self-efficacy; specifically, self-efficacy
for social activity and self-efficacy for mood
control. Seventy-one MS patients were initially
assessed through questionnaires, if they had been
obtained through a mailing list, or through an
interview, if they had been found as subjects
attending MS centers at the time of the study.
Assessment at the two month follow-up was
conducted via questionnaires. Self-efficacy for
mood control was measured through the SelfEfficacy Questionnaire for Mood Control, and
self-efficacy for social activity was assessed
using the Self-Efficacy for Social Activity
Questionnaire. Outcome measures for social
activity and mood control were determined by
looking at self-reported performance, also
assessed through questionnaires. The outcome
questionnaires consisted of lists of activities or
events considered to be representative of social
activity (P-Social) and mood control (P-Mood),
and subjects were asked to place tick marks next
to the activities or events they had participated in
over the two month period. Other outcome
measures included depression, assessed through
the Beck Depression Inventory; self-esteem,
measured using the Coopersmith Self-esteem
Inventory; and severity of illness, determined by
the physical dimension score of the Sickness
Impact Profile. Barnwell & Kavanagh (1997)
found self-efficacy for mood control to be a
significant predictor of mood control and social
activity, such that greater levels of self-efficacy
were predictive of greater levels of mood control
and higher amounts of social activity. Selfefficacy for social activity was a significant
predictor of mood control and social activity, that
is greater levels of social activity self-efficacy at
the baseline were associated with greater levels
of mood control and social activity at the two
month follow-up. Both types of self-efficacy
were significant predictors of depression; high
levels of self-efficacy were related to low levels
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of depression at the two month follow-up. Both
types of self-efficacy were also significant
piedictors of self-esteem, such that greater levels
of baseline self-efficacy were indicative of
greater levels of self-esteem at follow-up.
Lastly, both types of self-efficacy were significant predictors of severity of illness at the follow-up, such that greater levels of baseline selfefficacy were indicative of lower levels of
severity of illness at the follow-up.
Riazi et al. (2004) studied the relationship between self-efficacy and self-reported
health status in 89 MS patients admitted to the
National Hospital for Neurology and Neurosurgery for either rehabilitation treatment or intravenous steroid treatment. Baseline levels of selfefficacy were obtained upon hospital admission
and at discharge for patients involved in rehabilitation treatment, or six weeks later for patients
involved in intravenous steroid treatment. A
diagnosis of multiple sclerosis was assumed due
the admittance of the patients to the hospital for
MS related treatment. Self-efficacy was assessed
using the Multiple Sclerosis Self-Efficacy Scale,
which includes two subscales that look specifically at functional ability and at confidence in
functional abilities. The physical as well as the
psychological impact of MS on a person, one's
MS health status, was determined by the MS
Impact Scale (MSIS-29). Walking, generally
reflective of overall symptom severity, was
measured using the Multiple Sclerosis Walking
Scale. The inpatient rehabilitation treatment,
which is highly individualized, is generally
geared towards teaching problem-solving skills,
promoting goal-oriented decision-making, and
providing patients with overall techniques aimed
at reducing the toll MS takes on daily living.
Steroid treatment through the use of corticosteroids is used during MS relapses as a means of
controlling the symptoms associated with an
exacerbation and to prevent the relapse from
getting progressively worse.
Patients in the steroid group received lg
of methylprednisolone every day for three consecutive days. Baseline measures revealed that
patients who were part of the inpatient rehabilita-

tion program were significantly more disabled
than patients involved in the intravenous steroid
treatment group. Riazi et al. (2004) found that,
in both groups, greater self-efficacy scores were
associated with better health status at both
baseline and follow-up. It was also found that
better initial functional self-efficacy scores and
improvement in functional self-efficacy scores
were significantly related to improvement on all
outcome measures in both treatment groups. In
the rehabilitation group, improvement in the
control subscale of self-efficacy was a significant
predictor of improvement in health status scores,
as determined by the MSIS-29. In the steroid
group, baseline functional self-efficacy scores
were significant predictors of health status
scores, as determined by the MSIS-29. Furthermore, baseline self-efficacy control scores and
changes in functional self-efficacy and control
self-efficacy were significant predictors of all
outcome measures.
In a sample of 101 patients with relapsing-remitting multiple sclerosis, Mohr,
Boudewyn, Likosky, Levine, & Goodkin (2001)
studied the relationship between self-efficacy
and adherence to Interferon beta-la medication,
a drug treatment that must be injected weekly,
and that is aimed at slowing the progression of
multiple sclerosis and reducing the number and
intensity of exacerbations. Patients were selected from those MS patients approved to begin
this type of drug therapy, and were excluded if
they had had prior experience with self-injection,
since researchers were partly interested in
whether high injection anxiety would lead to
lower adherence. Patients' self-efficacy, injection anxiety, and adherence expectations were
assessed through questionnaires read to participants during telephone interviews two weeks
prior to the start of treatment, two weeks after
the onset of treatment, and at an eight week
follow-up. Self-efficacy was assessed using the
Injection Self-Efficacy Expectations Scale.
Other variables included injection anxiety, which
was measured through the Injection Anxiety
Expectations Scale; adherence expectations,
which were determined through the Adherence

17

Expectation Rating Scale; and illness severity,
which was assessed through the Guy's Neurological Disability Scale. Adherence was measured at the six month follow-up through patient
self-report and through confirmation from the
KPMC pharmacy that the patient was or was not
having their prescription refilled.
Mohr et al. (2001) found a significant
negative association between pre-treatment selfefficacy and pre-treatment anxiety. Injection
self-efficacy determined at the eight-week
follow-up was significantly related to posttreatment experienced injection anxiety, such
that the greater one's self-efficacy about the
ability to self-inject, the less self injection anxiety experienced. Injection self-efficacy was
found to be significantly related to Interferon
beta-la adherence at six months; however, this
relationship was found to be fully mediated by
the identity of the injection administrator (i.e. the
patient, the spouse, the health provider, etc.)
Thus, the relationship that exists between selfefficacy and adherence is not sufficient by itself,
but rather is completely dependent on the injection administrator.
Fraser, Morgante, Hadjimichael, &
Vollmer (2004) looked at self-efficacy as a
possible predictor of adherence to Glatiramer
Acetate (Copaxone) intravenous medication in a
convenience sample of 108 MS patients who had
already initiated therapy with Copaxone. Selfefficacy and other psychological variables were
assessed prior to beginning drug therapy, and
adherence was assessed at a six month followup. Self-efficacy was measured using the Multiple Sclerosis Self-Efficacy Scale (MSSE).
Adherence was defined, by self-report, as continuing therapy with Copaxone subcutaneously,
daily for at least six months. Fraser et al. (2004)
found self-efficacy to be a significant predictor
of adherence to Copaxone therapy, and the
adherent group had significantly higher selfefficacy scores than the non-adherent group.
Initial self-efficacy scores accurately predicted
adherence to Copaxone therapy at the six month
follow-up for 98.8% of those in the adherent
group.

Of the longitudinal correlational studies
reviewed, all four found a significant relationship between self-efficacy and at least one of the
outcome variables of interest. Significant positive correlations were found between selfefficacy and a number of desirable outcome
variables (e.g., mood control, social activity, selfesteem, health status, and adherence). Significant negative correlations were found between
self-efficacy and a number of adverse outcome
variables (e.g., depression, severity of illness,
and pre-treatment anxiety).
Retrospective Studies
Two of the studies reviewed were retrospective correlational studies. In both of these
studies, self-efficacy was assessed using the
Multiple Sclerosis Self-Efficacy Scale (MSSE)
in the present, and subjects were asked to reconstruct levels of adherence over the past year.
Fraser et al. (2001) were interested in the relationship between self-efficacy and adherence to
Copaxone therapy in 341 patients with relapsingremitting MS. Subjects included those who had
been adherent to Copaxone therapy for at least
the prior year (n=225), and those non-adherent to
Copaxone therapy during the prior year (n=116).
Researchers believed that self-efficacy scores
taken at the time of the study would be able to
correctly classify individuals as to whether they
had been adherent to Copaxone therapy during
the prior year. Adherence was defined as continuing therapy with Copaxone daily for at least
one year. Fraser et al. (2001) found the control
subscale of the self-efficacy measure to be a
significant predictor of adherence. The higher
one's score on the control subscale of the MSSE,
the more likely that individual was to have
adhered. The adherent group had significantly
greater self-efficacy that they could control their
MS. Functional self-efficacy, one's confidence
in his or her ability to function despite MS, was
not a significant predictor of adherence.
Fraser, Hadjimichael, & Vollmer (2003)
studied the strength of self-efficacy as a predictor
of adherence to Copaxone therapy in 199 subjects with progressive MS. Subjects included
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those who had been adherent and had taken
Copaxone for at least one year (n=107), and
those non-adherent who had discontinued
therapy before the end of the year (n=92). Therefore, researchers were interested in whether selfefficacy measures, obtained at the time of the
study, could properly classify individuals as to
whether they had adhered or not adhered to
Copaxone therapy during the prior year. Fraser
et al. (2003) found both subscales of self-efficacy, the control subscale and the function
subscale, to be significant predictors of adherence. The greater one's score on the MSSE, the
more likely that individual was to have adhered.
Both retrospective correlational studies reviewed
found a significant positive relationship between
self-efficacy and adherence to Copaxone therapy.

scores. However, there was no significant
improvement in mental health as a result of
treatment. Hence, the only quasi-experimental
study reviewed found no relationship between
self-efficacy and mental health.

Discussion

Summary of Findings
Of the 11 studies reviewed, almost all
'
report a statistically significant relationship
between self-efficacy and at least one of the
outcome variables tested. However, there is still
some disparity over which variables can be
significantly predicted by self-efficacy, because
while some studies report a significant relationship with a specific outcome variable, other
studies fail to detect this relationship. All six
studies that looked at the relationship between
Quasi-experimental Studies
self-efficacy and health promoting behaviors
One of the studies was a within-subjects
such as level of physical activity, level of social
(pre-post) quasi-experimental study. In this
activity, and adherence to medical regimens, and
study, random assignment was not used, and
related feelings about health promoting behavthus, the study must be considered a quasiiors (such as perceived barriers to health promotexperimental study, since true experimental
ing behaviors and belief in availability of redesigns require random assignment. The fact
sources), found significant relationships. While
that all subjects were assigned to the intervention most of these studies looked at the health promakes this study a within-subjects design.
moting variable of adherence to MS medication,
Wingerson & Wineman (2000) considered the
and relatively few considered other health prorelationship between self-efficacy and overall
moting behaviors, all four studies that considered
mental health during a community-based treatadherence found a statistically significant relament involving a convenience sample of 12
tionship between self-efficacy and treatment
subjects with MS who indicated a need for
adherence. Furthermore, adherence was assessed
counseling. All subjects participated in the
in these studies over a relatively long period of
short-term counseling intervention, which
time, ranging from six months to one year,
consisted of individualized therapy based on the lending them fairly good credibility. Generally,
person's particular needs. Self-efficacy was
the longer the follow-up period, the greater the
measured prior to the beginning of the intervenstrength of the findings. Studies that have longer
tion and at the conclusion of the intervention,
follow-up periods are more likely to detect true
using a modified version of the Self-Efficacy
effects as opposed to chance findings or shortInstrument. The outcome variable mental health lived relationships that may be present immediwas assessed through the Mental Health Invenately following an intervention. Because of this,
tory. All measures were assessed at pre-treatstudies that use longer follow-ups are generally
ment and at post-treatment, and pre-treatment
accepted as methodologically stronger than those
measures were used to formulate individual
studies that have relatively short follow-ups.
treatment plans. Wingerson & Wineman (2000) These findings suggest that it may be beneficial
found a significant improvement in self-efficacy for treatment centers to consider a person's selfwhen comparing pre and post self-efficacy
efficacy before starting him or her on intrave-
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nous MS medications, because people with low
self-efficacy may not benefit from this treatment
without further intervention to improve their
level of self-efficacy. The remaining studies,
focusing on the relationship between self-efficacy and health promoting behaviors, considered
different outcome variables, and thus were
unable to replicate findings and establish proof
of a real relationship. However, because all
relationships considered between self-efficacy
and health promoting behaviors were found to be
significant, it is likely that self-efficacy is related
to health promoting behaviors, and that selfefficacy may serve as a predictor of adherence,
level of physical activity, and other health promoting activities.
Of the six studies that considered the
relationship between self-efficacy and physical
symptom severity, functional impairment, fatigue, health status, and overall illness severity,
three found significant relationships, two did not
find a statistically significant relationship, and
one had somewhat inconsistent results, finding a
significant relationship between one of the
health-related variables and self-efficacy, but
failing to find a significant relationship between
self-efficacy and the other health-related variable. Ultimately, most of the discrepancy had to
do with the relationship between self-efficacy
and illness severity, with two studies finding a
significant relationship and one not. While
clearly the association between self-efficacy and
health status is questionable based on this review, these results may be attributable to the way
in which health status was measured. For example, studies that provided purely physical
assessments of health status, such as functional
impairment or extent of disability—excluding
more subjective symptoms such as fatigue—
generally did not find a statistically significant
relationship with self-efficacy. However, studies
that employed a more subjective measure of
disability (e.g., perceived illness severity or
perceived health status) often did find a significant relationship with self-efficacy. This suggests that self-efficacy may influence people's
subjective assessments of their overall health

status, and that those with greater self-efficacy
may downplay the negative aspects of their
illness and exercise the sense of control they
believe they have over its severity. However,
when these same subjects are asked to objectively report the severity of specific physical
symptoms of their disease, such as the extent of
their disability or the actual impairment they
face, self-efficacy may not be related to their
actual physical state. In other words, perceived
self-efficacy may be significantly related to
variables such as perceived severity of illness
because having self-efficacy allows people to
look past the specific physical problems they
may encounter and still maintain a positive sense
of control over the extent of their disability. At
the same time, self-efficacy may not be related to
symptom severity or severity of impairment
because, while self-efficacy may give people a
more positive attitude, it does not allow them to
overlook specific physical shortcomings. This is
not surprising, given the fact that self-efficacy is
fundamentally defined in terms of self-perception. Thus, outcome variables which depend, in
large part, on perception may be more strongly
related to self-efficacy than more objective
variables.
Out of four studies that looked at the
relationship between self-efficacy and psychological outcomes, including mental health status,
feelings of helplessness, cognitive distortions,
depression, mood control, and self-esteem, half
found a significant relationship and half did not.
Most of the inconsistency had to do with the
relationship between self-efficacy and depression; two studies found a significant relationship
and one did not. Due to this inconsistency,
further research must be done before a relationship can be established between self-efficacy and
depression. However, studies that focused on the
relationship between self-efficacy and other
psychological components did find a significant
relationship with cognitive distortions, feelings
of helplessness, mood control, and self-esteem,
suggesting that self-efficacy may be associated
with other cognitive components. It is reasonable to assume that self-efficacy, defined as the
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belief of control one feels over one's MS, may
impact other cognitive aspects such as feelings
of helplessness and self-esteem, because these
psychological components are also largely
affected by self-perception. People with greater
self-efficacy, who feel strength in their ability to
control their MS and their future, likely perceive
themselves in a better light and probably have
fewer feelings of helplessness and greater selfesteem than individuals with low self-efficacy.
However, because these relationships were not
repeatedly tested and their findings replicated,
one cannot be certain as to whether a true relationship exists.
Lastly, of the two studies that looked at
perceived quality of life, including acceptance of
illness and overall adjustment to illness, both
found statistically significant relationships.
Clearly, it is conceivable that individuals with
greater self-efficacy would report a greater
perceived quality of life and likely consider
themselves to be more adjusted and more accepting of their illness than those with low selfefficacy. However, one must hesitate before
drawing this conclusion based on the limited
amount of research that has been done in this
area. Further research is necessary before a
relationship between self-efficacy and perceived
quality of life can be deemed credible, and
replication is vital before a relationship between
self-efficacy and the above mentioned variables
can be confirmed.
Strengths of the Literature Reviewed
There are several strengths to the literature reviewed in this paper. Almost all of the
correlational studies had moderate to large
sample sizes. Furthermore, of these studies,
those that performed an analysis of the demographic characteristics of their sample found
their sample to be a fairly accurate representation
of the MS population-samples were largely made
up of white, middle-age women. Having a
moderate to large sample size increases the
likelihood of also having a representative
sample, and a representative sample allows one
to generalize findings to the greater population

with more confidence.
Another strength of the literature reviewed in this paper is that, methodologically,
many of the variables of interest were assessed
using instruments demonstrated to be internally
consistent. For example, four of the studies used
the Multiple Sclerosis Self-Efficacy Scale
(MSSE) as a measure of self-efficacy, a scale
developed specifically to measure self-efficacy in
MS patients, with a recognized overall alpha of
around .89 (Schwartz, Coulthard-Morris, Zeng,
& Retzlaff, 1996, as cited in Fraser et al., 2003 ).
Shnek et al. (1997) also report an alpha of .89 for
the Beliefs Scale, used to assess self-efficacy in
their study. Wassem (1992) reports Cronbach's
alpha for the Self-Efficacy for Adjustment
Behaviors Scale to be .91. Barnwell &
Kavanagh (1997) report the internal consistency
of the two subscales of their self-efficacy measures, self-efficacy for mood control and selfefficacy for social activity, to be .91 and .90,
respectively. Furthermore, in all but two of the
studies reviewed, researchers report the selfefficacy scale used to have been previously
proven valid and reliable. In Wingerson &
Wineman (2000) test-retest reliability for the
Self-Efficacy Instrument is reported to be between. .82 and .89, and construct validity between .14 to .68. It is important that the instruments used are internally consistent, as well as
valid and reliable, because if they are not, then
one cannot be completely confident in the findings, even if they are statistically significant.
Weaknesses of the Literature Reviewed
Unfortunately, there are many shortcomings to the literature reviewed. Methodologically, there were no true experiments conducted
to test the relationship between self-efficacy and
any of the outcome variables of interest. This
means that a cause and effect relationship cannot
be established. Furthermore, there was only one
quasi-experimental study, and that study was
quite weak, with an extremely small sample size
and no control group. While quasi-experimental
studies are inherently weak due to their lack of
random assignment, often this weakness can be
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offset, at least in part, by the presence of a
control group, which can be compared to the
experimental group in order to determine
whether a cause and effect relationship is likely.
However, the quasi-experimental study reviewed
did not have a control group, which means that
one cannot be certain that the findings were a
result of a change in self-efficacy and indicative
of a true cause-and-effect relationship, or
whether the results were attributable to some
specific factor associated with the treatment. In
order to eliminate this possibility, one must
always include a control group.
The lack of experimental studies also
makes it difficult to identify a cause-and-effect
relationship because confounds cannot be controlled. For example, one health promoting
behavior tends to be associated with other health
promoting behaviors. That is, an individual who
partakes in a health promoting behavior (e.g.,
exercising), is likely to also partake in other,
related health promoting behaviors (e.g., healthy
diet or not smoking). Because of this, it is
almost impossible to determine, based strictly on
a significant correlational relationship, whether a
finding is indicative of a cause-and-effect relationship, a by-product of an outcome variable, or
a result of other related outcome variables. In
other words, if a statistically significant relationship was detected between self-efficacy and
exercising, this finding may be reflective of a
true cause-and-effect relationship, whereby one
of the variables causes changes in the other
variable. However, it may also be the case that
the finding is attributable to a relationship
between self-efficacy and a by-product of exercise (e.g., increased self-esteem).
Because all but one of the studies reviewed were correlational in nature, it is impossible to determine with certainty whether a true
relationship exists, or whether the observed
association is a result of each variables' relationship with a third variable. For example, in terms
of the presumed relationship between selfefficacy and health promoting behaviors, it could
be that the relationship between self-efficacy and
health promoting behaviors is determined by a

third variable, such as illness severity, or by
another psychological component such as optimism. If self-efficacy and illness severity are
highly correlated, and illness severity and health
promoting behaviors are highly correlated, then,
while it may appear statistically that self-efficacy
and health promoting behaviors are highly
correlated, this may not be indicative of an
underlying cause-and-effect relationship at all.
Instead, illness severity may be affecting both
self-efficacy and health promoting behaviors—
with greater illness severity resulting in lower
levels of self-efficacy and lower levels of health
promoting behaviors. Thus, each variable's
relationship to illness severity might create the
appearance of a cause-and-effect relationship,
when in reality no such relationship exists.
Another problem with this heavy reliance
on correlational studies, especially cross-sectional studies, is that they cannot determine with
confidence the direction of a relationship. For
example, in considering the findings of
Vercoulen et al. (1998), one can speculate that
higher self-efficacy causes people to partake in
greater amounts of physical activity. However, it
could be the case that partaking in greater
amounts of physical activity causes people to
have greater strength in their belief that they can
control their MS. When data are obtained at
only one point in time, as they are with crosssectional studies, it is almost impossible to
determine directionality with a high degree of
confidence.
Another weakness is that none of the
studies reviewed were prospective studies. This
means that the effects of self-efficacy on MS can
only be looked at after the disease has manifested itself and a diagnosis has been made.
Whether a higher or lower level of self-efficacy
has an effect on the onset of MS, or on factors
that lead to the development of multiple sclerosis
cannot be determined.
Only three of the correlational studies
reviewed included follow-ups, and the follow-up
periods were relatively short, ranging from two
to six months. Clearly, longitudinal studies are
methodologically stronger than cross-sectional
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and retrospective studies, because there is a
greater likelihood that true effects will be detected, as opposed to temporary effects or chance
findings. When trying to determine whether selfefficacy has an effect on the physical symptoms
of MS, longitudinal studies are much preferred.
If the effects of self-efficacy were present only
for a short time period following a treatment,
cross-sectional studies or longitudinal studies,
where the follow-up time is minimal, would
misinterpret the effects of self-efficacy as longlasting, when in fact they may be temporary.
Further, if the effects of self-efficacy were
delayed, even longitudinal studies may not detect
this relationship if the follow-up periods are
short. Especially in terms of physical symptomatology, whether findings are considered significant is determined largely by the degrees of
protective effects offered and the lengths of time
that the protective effects last. Thus, in order for
self-efficacy to be viewed as a valuable tool for
reducing the impact of symptoms or lessening
overall illness severity, the long-term effects of
self-efficacy would have to be demonstrated. In
order to accomplish this, it would be necessary
to follow a group of MS patients for several
years, in order to see whether levels of selfefficacy could predict exacerbations of MS.
Suggestions for Future Research
Taking into consideration the several
strengths and the numerous flaws of the reviewed literature, an ideal study looking at the
relationship between self-efficacy and health
promoting behaviors, physical symptoms and
illness severity, mental health, and quality of life
would include an experimental design with a
long-term follow-up. Ideally, one might want to
use a prospective design. However, because so
little is known about the cause of MS, many
resources may be wasted using this design on
large groups of individuals who might never
develop MS. A more productive study would
consist of an experimental between-subjects
design, that includes a large group (n=500) of
MS patients. Pre-test measures would be obtained through the use of questionnaires on self-

efficacy, health promoting behaviors, mental
health, physical symptomatology, and perceived
quality of life, and then patients would be randomly assigned to either a treatment condition or
a control condition. If a large sample could not
be obtained, then surely subjects would need to
be matched on important disease characteristics,
such as extent of disability. The treatment
condition would involve self-efficacy training,
and following the intervention, post-test measures would be obtained. While multi-modal
treatments that involve stress management
training or teaching coping skills may be considered more effective overall, using this type of
treatment approach to address the question at
hand would not be desirable. Using a multimodal treatment approach, where the treatment
is multi-faceted, causes later ambiguity because
it is difficult to distinguish between and determine the effectiveness of different components
of the treatment, as it is also difficult to determine whether the observed results were the
result of an interaction between some of the
treatments and not others. Thus, multi-modal
treatments complicate matters when trying to
establish a causal relationship and identify a
relationship between self-efficacy and the variables in question. Furthermore, including a
long-term follow-up, perhaps testing subjects on
all measures every six months for ten years,
would provide a much more accurate picture of
the relationship between self-efficacy and outcome variables such as health promoting behaviors, symptom and overall illness severity,
mental health status, and perceived quality of life
in MS patients, and also provide a better understanding about the strength of these relationships. Also, using a long-term follow-up would
allow for a better look into the possible relationship between self-efficacy and symptom severity,
because it is likely that subjects would experience exacerbations during a longer time period,
and self-efficacy could be assessed in relation to
these symptomatic relapses.
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